<DOC>
	<DOC>NCT01656161</DOC>
	<brief_summary>The primary purpose of this study is to evaluate the efficacy of triptorelin embonate 22.5 mg 6-month formulation administered by the subcutaneous (under the skin) route in: - achieving castrate levels of testosterone (&lt; 1.735 nmol/L) on Day 29 [i.e., 28 days after investigational medicinal product (IMP) injection], and - in maintaining serum testosterone castrate levels from Month 2 (Day 57) to end of Month 12 (Day 337) in participants with advanced prostate cancer.</brief_summary>
	<brief_title>Study on Efficacy, Pharmacokinetics, and Safety of Two Subcutaneous Injections of Triptorelin Embonate 6 Month Formulation in Patients With Advanced Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Triptorelin Pamoate</mesh_term>
	<criteria>Summary Meets protocolspecified criteria for qualification and contraception Is willing and able to remain confined in the study unit for the entire duration of each treatment period and comply with restrictions related food, drink and medications Voluntarily consents to participate and provides written informed consent prior to any protocolspecific procedures Summary Has history or current use of overthecounter medications, dietary supplements, or drugs (including nicotine and alcohol) outside protocolspecified parameters Has signs, symptoms or history of any condition that, per protocol or in the opinion of the investigator, might compromise: 1) the safety or wellbeing of the participant or study staff; 2) the safety or wellbeing of the participant's offspring (such as through pregnancy or breastfeeding); 3) the analysis of results</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>